Clinical characteristics were similar to those reported in trials investigating single-agent anti-PD-1/PD-L1, though our cohort had a considerably lower proportion of patients in the favorable International Metastatic RCC Database Consortium (IMDC) risk group [2,15]. This evidence concerns the gene CD274 and renal cell carcinoma.